8-K: Immuneering Reports Strong Interim Phase 2a Data for Pancreatic Cancer Drug Atebimetinib, Plans Pivotal Trial

Immuneering Corporation announced encouraging interim Phase 2a clinical trial results for its MEK inhibitor atebimetinib in combination with mGnP for first-line pancreatic cancer, showing an 81% disease control rate and a 39% overall response rate, with plans for a pivotal trial in 2026.

Summary

• Immuneering Corporation announced interim data from its ongoing Phase 2a clinical trial arm evaluating atebimetinib in combination with modified Gemcitabine/nab-Paclitaxel (mGnP) in first-line pancreatic cancer patients.
• As of the May 26, 2025 cutoff date, among 36 response evaluable patients, the interim Disease Control Rate (DCR) was 81% (29/36) and the interim Overall Response Rate (ORR) was 39% (14/36), as measured by RECIST.
• The responses included one complete response, 13 partial responses (with four pending confirmation), 15 stable diseases, and seven progressive diseases.
• In the intent-to-treat population of 34 patients dosed at the 320 mg once-daily level, 94% overall survival (OS) and 72% progression-free survival (PFS) were observed with a median follow-up time of six months, with neither median OS nor median PFS having been reached.
• Atebimetinib in combination with mGnP was generally well tolerated; Grade ≥3 treatment-emergent adverse events (TEAEs) observed in 10% or greater of patients were limited to Anemia (18%, 6 patients) and Neutropenia (15%, 5 patients), with no Grade 5 TEAEs.
• The company expects additional data from the Phase 2a portion of the trial in the fourth quarter of 2025.
• Immuneering plans to initiate a pivotal trial evaluating atebimetinib in combination with mGnP in first-line pancreatic cancer patients in 2026, pending regulatory feedback expected in the fourth quarter of 2025.
• Additional clinical trial combination arms evaluating atebimetinib are also planned for initiation in 2026.

Sentiment

Score: 8

Explanation: The interim clinical trial results for atebimetinib in pancreatic cancer are highly positive, demonstrating strong efficacy metrics (DCR, ORR, early OS/PFS) and a manageable safety profile in a disease with significant unmet medical need. The clear path to a pivotal trial indicates strong confidence in the drug's potential. While the data is interim, the initial signals are very encouraging.

Positives

• High interim Disease Control Rate (DCR) of 81% (29/36) in first-line pancreatic cancer patients, indicating significant disease control.
• Encouraging interim Overall Response Rate (ORR) of 39% (14/36), including one complete response, demonstrating tumor shrinkage.
• Strong interim overall survival (OS) of 94% and progression-free survival (PFS) of 72% in the 320 mg ITT population after a median follow-up of six months, suggesting a positive impact on patient longevity and disease progression.
• Neither median OS nor median PFS had been reached, indicating the durability of the observed benefits extends beyond the current follow-up period.
• Atebimetinib in combination with mGnP was generally well tolerated, with manageable Grade ≥3 adverse events (Anemia 18%, Neutropenia 15%) and no Grade 5 TEAEs, suggesting a favorable safety profile for patients.
• The company's plan to initiate a pivotal trial in 2026 signals confidence in the drug's potential and a clear path towards regulatory approval.

Negatives

• Four partial responses are pending confirmation at a subsequent scan, which could slightly alter the final reported Overall Response Rate.
• Seven patients (19%) showed progressive disease, indicating that the treatment was not effective for all patients in the response-evaluable group.
• The data presented is interim, and longer-term follow-up is necessary to fully confirm the durability of responses and the complete safety profile.

Risks

• Risks inherent in oncology drug development, including the uncertainties and challenges associated with clinical trials.
• Actual results may differ from forward-looking statements due to inherent uncertainties, risks, and assumptions that are difficult to predict.
• Important factors discussed under 'Risk Factors' in the company's Annual Report on Form 10-K for the year ended December 31, 2024, and Quarterly Report on Form 10-Q for the three-month period ended March 31, 2025, could cause actual results to differ materially from those indicated by forward-looking statements.

Future Outlook

Immuneering Corporation anticipates releasing additional data from the Phase 2a portion of its atebimetinib trial in the fourth quarter of 2025. Subject to regulatory feedback, also expected in the fourth quarter of 2025, the company plans to initiate a pivotal trial for atebimetinib in combination with mGnP in first-line pancreatic cancer patients in 2026. Furthermore, the company intends to initiate additional clinical trial combination arms for atebimetinib in 2026.

Management Comments

• "Any such forward-looking statements represent management's estimates as of the date of this Current Report."
• "While we may elect to update such forward-looking statements at some point in the future, unless required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change."
• "These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this Current Report."

Industry Context

Pancreatic cancer remains one of the most challenging malignancies to treat, characterized by aggressive progression and a historically poor prognosis, particularly in the first-line metastatic setting. Current standard-of-care chemotherapy regimens, while offering some benefit, are often associated with significant toxicities and limited long-term survival. The interim data for atebimetinib, a MEK inhibitor, in combination with mGnP, represents a potentially significant advancement. The high disease control rate, overall response rate, and early survival data observed in this trial suggest a promising new therapeutic avenue for this high unmet need patient population. This aligns with the broader oncology industry trend towards developing targeted therapies and combination regimens that can improve efficacy and tolerability over traditional chemotherapy.

Comparison to Industry Standards

• For first-line metastatic pancreatic cancer, standard chemotherapy regimens like FOLFIRINOX or Gemcitabine/nab-Paclitaxel typically yield median overall survival (OS) ranging from 8 to 12 months. Immuneering's observed 94% OS and 72% progression-free survival (PFS) at a median follow-up of six months are highly encouraging and appear to exceed historical benchmarks, though longer-term data is needed for definitive comparison.
• Overall response rates (ORR) for standard first-line treatments in pancreatic cancer generally fall within the 20-35% range. Immuneering's interim ORR of 39% (14/36) is competitive and potentially superior to these established therapies.
• The reported Disease Control Rate (DCR) of 81% is also robust when compared to typical DCRs seen with standard regimens in this aggressive disease.
• The safety profile, with Grade ≥3 TEAEs limited to Anemia (18%) and Neutropenia (15%) and no Grade 5 events, suggests a manageable toxicity profile. This is a critical advantage, as intensive chemotherapy regimens often lead to more severe and debilitating side effects, impacting patient quality of life and treatment adherence.

Stakeholder Impact

• Shareholders: The positive interim clinical data is highly likely to increase investor confidence and could lead to a significant positive impact on the company's share price due to the promising outlook for a key pipeline asset.
• Patients: The encouraging results offer significant hope for a new, effective, and potentially better-tolerated treatment option for first-line pancreatic cancer, a disease with a very high unmet medical need and poor prognosis.
• Healthcare Providers: If approved, atebimetinib could become a valuable addition to the therapeutic arsenal for pancreatic cancer, potentially improving patient outcomes and treatment strategies.
• Employees: Positive clinical progress can boost morale, attract talent, and provide job security as the company moves closer to potential commercialization and expands its clinical development programs.

Next Steps

• Release additional data from the Phase 2a portion of the atebimetinib trial in the fourth quarter of 2025.
• Receive regulatory feedback regarding the pivotal trial in the fourth quarter of 2025.
• Initiate a pivotal trial evaluating atebimetinib in combination with mGnP in first-line pancreatic cancer patients in 2026.
• Initiate additional clinical trial combination arms evaluating atebimetinib in 2026.

Key Dates

Recommendation

Keywords

Immuneering Corporation, IMRX, atebimetinib, MEK inhibitor, pancreatic cancer, clinical trial, Phase 2a, oncology, drug development, disease control rate, overall response rate, overall survival, progression free survival, Gemcitabine/nab-Paclitaxel, mGnP, RAS-mutant, RAF-mutant, solid tumors, biotechnology, pharmaceuticals